Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
View this publicationMember
PD Dr. med. Niklas Klümper, an advanced clinician-scientist in the ACCENT program at the University Hospital Bonn, focuses on uro-oncology and aims to improve treatment response predictions for targeted therapies, leading to more personalized approaches for uro-oncological diseases. His team has pioneered the prediction of immune checkpoint blockade responses through the analysis of longitudinal inflammatory markers, contributing to the field of immuno-oncology. They are also investigating the mechanisms of resistance to antibody-drug conjugates in patients with metastatic urothelial carcinoma, an emerging area of oncological therapies, and aim to improve precision oncology by tailoring treatment to the molecular profile of patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
View this publicationEuropean urology focus
View this publicationAmerican journal of respiratory and critical care medicine
View this publication